Cargando…

Thyroid Cancer A Comprehensive Guide to Clinical Management /

Thoroughly revised and extensively expanded, this encyclopedic, highly acclaimed title addresses all aspects of the etiology, pathogenesis, diagnosis, initial treatment and long-term management of all varieties of thyroid cancer. Expertly edited by Drs. Leonard Wartofsky and Douglas Van Nostrand, th...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Wartofsky, Leonard (Editor ), Van Nostrand, Douglas (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York, NY : Springer New York : Imprint: Springer, 2016.
Edición:3rd ed. 2016.
Temas:
Acceso en línea:Texto Completo
Tabla de Contenidos:
  • PART I. General Considerations I: THYROID CANCER
  • 1 Anatomy and Physiology of the thyroid gland: Clinical Correlates to Thyroid Cancer
  • 2 Epidemiology of Thyroid Cancer
  • 3 Molecular Pathogenesis of Thyroid Cancer & Oncogenes in Thyroid Cancer.- 4 Molecular Aspects of Thyroid Cancer in Children
  • 5 The Role of Genetics in the Development of Familial Non-Medullary Thyroid Cancer
  • 6 Apoptosis in Thyroid Cancer
  • 7 Radiation-Induced Thyroid Cancer
  • 8 Classification of Thyroid Malignancies.- 9 Staging of Thyroid Cancer
  • 10 Recombinant human Thyrotropin (Thyrogen®)
  • PART II. GENERAL CONSIDERATIONS II: NUCLEAR MEDICINE
  • 11 Radioiodine Whole Body Imaging
  • 12 Primer and Atlas for the Interpretation of Radioiodine Whole-Body Scintigraphy
  • 13 False-Positive Radioiodine-131 scans in Thyroid Cancer
  • 14 The Utility of SPECT-CT in Differentiated Thyroid Cancer
  • 15 Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for staging and risk stratification
  • 16 Stunning by 131I scanning: Untoward Effect of 131I Thyroid Imaging Prior to Radioablation Therapy
  • 17 Stunning is Not a Problem.- 18 Stunning: Does it Exist? A Commentary
  • 19 To Perform or Not to Perform Radioiodine Scans Prior to 131I Remnant Ablation?.- PART III. THE THYROID NODULE
  • 20 The Thyroid Nodule: Evaluation, Risk of Malignancy, and Management
  • 21 Fine-Needle Aspiration
  • 22 Diagnostic and Prognostic Molecular Markers in Thyroid Cancer
  • 23 Ultrasonic Imaging of the Thyroid Gland.- 24 Radionuclide Imaging of Thyroid Nodules
  • 25 18F Fluoro-deoxyglucose PET and Thyroid Nodules
  • 26 Thyroid Nodules and Cancer Risk: Surgical Management
  • 27 Thyroid Nodules in Children and Cancer Risk
  • 28 Management of the Thyroid Nodule: A Comparison Of Published International Guidelines
  • PART IV. WELL-DIFFERENTIATED THYROID CANCER A: PAPILLARY CARCINOMA: PRESENTATION
  • 29 Papillary Carcinoma: Clinical Aspects
  • 30 Papillary Microcarcinoma
  • 31 Surgical Approach to Papillary Thyroid Cancer
  • 32 Papillary Carcinoma: Cytology and Pathology
  • B. INITIAL MANAGEMENT
  • 33 Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131I
  • 34 Thyroid Remnant Radioiodine Ablation with Recombinant Human Thyrotropin
  • C. SURVEILLANCE
  • 35 Follow-up Strategy in Papillary Thyroid Cancer
  • 36 Thyroid Hormone Therapy and Thyrotropin Suppression
  • 37 Thyroglobulin for Differentiated Thyroid Cancer: Measurement and Interferences.- 38 Thyroglobulin Antibodies and Their Measurement
  • 39 Diagnosis of Recurrent Thyroid Cancer in Patients with Anti-Thyroglobulin Antibodies
  • 40 Ultrasound of the neck lymph nodes
  • 41 Surveillance Radioiodine Whole Body Scans
  • 42 Radionuclide Imaging and Treatment of Children with Thyroid Cancer
  • 43 Positron Emission Tomography-/Computed Tomography (PET-CT and PET) in Well-Differentiated Thyroid Cancer
  • 44 Alternative Thyroid Imaging
  • 45 MR and CT Imaging of Thyroid Cancer
  • 46 Thyroglobulin in Lymph Node Aspirate
  • 47 Management of the Patients with Negative Radioiodine Scan and Elevated Serum Thyroglobulin
  • 48 Prognosis in Papillary Thyroid Cancer
  • 49 Surgical Management of Lymph Node Metastases.- 50 Utility of Second Surgery for Lymph Node Metastases
  • 51 Papillary Cancer Special Aspects in Children
  • 52 Special Presentations of Thyroid Cancer in Thyrotoxicosis, Renal Failure, and Struma Ovarii
  • 53 Thyroglossal Duct Carcinoma
  • 54 Thyroid Cancer in Pregnancy
  • D. TREATMENT
  • 55 Radiation and Radioactivity
  • 56 131I Treatment of Distant Metastases
  • 57 Treatment of Metastatic Thyroid Cancer with Radioiodine following preparation by Recombinant Human Thyrotopin
  • 58 Dosimetrically-Determined Prescribed Activity of 131I for the Treatment of Metastatic Differentiated Thyroid Carcinoma
  • 59 Simplified Methods of Dosimetry
  • 60 Radioiodine Dosimetry with Recombinant human Thyrotropin
  • 61 The Use of Lithium as an Adjuvant to Radioiodine In the Treatment of Thyroid Cancer
  • 62 Side Effects of 131I for Therapy of Differentiated Thyroid Carcinoma.- 63 Radiation Therapy in Papillary Carcinoma
  • 64 Chemotherapy of Thyroid Cancer: General Principles
  • 65 Bone Metastases from Differentiated Thyroid Carcinoma
  • 66 A Summary of Rare Sites of Metastasis Secondary to Differentiated Thyroid Cancer.- 67 Adjunctive Local Approaches to Thyroid Nodules and Metastatic Thyroid Cancer
  • 68 Radioiodine-Refractory Thyroid Cancer: Restoring Response to Radioiodine Therapy
  • 69 Alternative and Complementary Treatment of Thyroid Disorders
  • PART V. WELL-DIFFERENTIATED THYROID CANCER  FOLLICULAR CARCINOMA
  • 70 Follicular Thyroid Carcinoma
  • 71 Surgical Management of Follicular Cancer
  • 72 Pathology of Follicular Cancer
  • 73 Hürthle Cell Carcinoma
  • 74 Follow-Up Strategy in Follicular Thyroid Cancer
  • 75 Radionuclide Imaging and 131I Therapy in Follicular Thyroid Carcinoma
  • 76 PET/CT in Follicular Cancer Including Hürthle Cell Cancer
  • 77 Follicular Thyroid Cancer: Special Aspects in Children and Adolescents
  • 78 External Radiation Therapy of Follicular Carcinoma
  • 79 Determinants of Prognosis of Follicular Thyroid Carcinoma
  • PART VI. VARIANTS OF THYROID CANCER.- 80 Aggressive Variants of Papillary Thyroid Carcinoma and Poorly Differentiated Carcinoma
  • 81 Miscellaneous and Unusual Tumors of the Thyroid Gland
  • 82 Pathology of Miscellaneous and Unusual Tumors of the Thyroid Gland
  • PART VII. UNDIFFERENTIATED TUMORS: MEDULLARY THYROID CARCINOMA
  • 83 Clinical Aspects of Medullary Thyroid Carcinoma
  • 84 Cytology and Pathology of Medullary Carcinoma
  • 85 Medullary Carcinoma of the Thyroid: Surgical Management
  • 86 Radionuclide Imaging of Medullary Carcinoma
  • 87 PET/CT in Medullary Thyroid Cancer
  • 88 Radiation Therapy in Medullary Cancer
  • 89 Medullary Carcinoma of the Thyroid: Chemotherapy
  • 90 A Comparison of the ATA, NCCN, ETA, and BTA Guidelines for the Management of Medullary Thyroid Cancer
  • PART VIII. UNDIFFERENTIATED TUMORS:  THYROID LYMPHOMA
  • 91 Thyroid Lymphoma
  • 92 Pathology of Lymphoma of the Thyroid
  • 93 PET/CT in Lymphoma and Lymphoma of the Thyroid
  • PART IX. UNDIFFERENTIATED TUMORS: ANAPLASTIC THYROID CANCER
  • 94 Anaplastic Thyroid Carcinoma:  Clinical Aspects
  • 95 Surgical Management of Anaplastic Thyroid Carcinoma
  • 96  Pathology of Anaplastic Carcinoma
  • 97 PET/CT in Anaplastic Cancer of the Thyroid
  • 98 Anaplastic Thyroid Cancer
  • 99 Chemotherapy for Anaplastic Thyroid Cancer
  • 100 Anaplastic Thyroid Carcinoma:  Prognosis
  • PART X. NEW FRONTIERS AND FUTURE DIRECTIONS
  • 101 Advances in Radiation Therapy
  • 102 New Approaches in Nuclear Medicine for Thyroid Cancer
  • 103 124I in Differentiated Thyroid Cancer
  • 104 Future Directions for Advanced Thyroid Cancer Therapy
  • 105 Potential Approaches to Chemotherapy of Thyroid Cancer in the Future
  • PART XI. Additional Resources.- 106 Prophylaxis against Radiation Exposure from Radioiodine
  • 107 Low Iodine Diets
  • 108 Appendix A: Books and Manuals
  • 109 Appendix B: Additional Sources of Information: Support groups, Websites and additional information
  • 110 Appendix C:   Forms and Instructions for Patients Treated with Radioactivity.